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KAJIAN EKSPLORASI PADA KESAN ADVERS DAN KERINTANGAN 
UBAT TUBERCULOSIS DALAM KALANGAN PESAKIT TUBERCULOSIS  
DI HOSPITAL PULAU PINANG, MALAYSIA 
 
ABSTRAK 
 Tuberculosis (TB), penyakit berjangkit disebabkan oleh Mycobacterium 
tuberculosis yang banyak menyebabkan banyak kematian sepanjang sejarah hidup 
manusia, kini menjadi penyebab kedua terbesar penyebab kematian antara penyakit 
berjangkit yang ada setelah HIV-AIDS. Rawatan TB memerlukan kombinasi ubat 
anti-TB. Kesan advers drug anti-TB menjadi penting kerana kegunaan jangka masa 
panjang ubat anti-TB. Selain kesan advers drug anti-TB, munculnya bakteria TB 
rintang ubat anti-TB dapat menyulitkan rawatan TB pesakit. 
Kajian ini adalah kajian retrospektif lintang secara pengamatan. Subjek 
penyelidikan kajian ini adalah pesakit yang dirawat sebagai pesakit TB di Klinik 
Dada, Hospital Pulau Pinang, Malaysia. Kajian ini bertujuan untuk menyiasat kesan 
advers drug anti-TB, adanya bakteria TB rintang ubat anti-TB, dan menyiasat faktor 
yang berkaitan dengan kesan advers drug TB dan rintang ubat anti-TB serta keluaran 
klinikal pesakit TB. Kesan advers drug anti-TB dilihat berdasarkan gejala klinikal, 
keputusan ujian makmal, dan maklumat lain yang berkaitan, sementara adanya 
bakteria TB rintang ubat anti-TB dilihat berdasarkan diagnosis yang bergantung 
kepada hasil ujian kecenderungan ubat atau ujian sensitiviti bakteria. Data demografi 
pesakit, sejarah perubatan, diagnosis TB dan rawatan, tanda dan gejala kesan advers 
drug, keputusan ujian makmal, ujian sensitiviti bakteria, dan maklumat lain yang 
berkaitan dikumpulkan. Data yang diperoleh dianalisis dengan menggunakan 
Statistic Package for Social Science (SPSS® versi 1.15). 
xvi 
 
 Hasil analisis kajian menunjukkan bahawa daripada 653 pesakit termasuk 
dalam kajian ini, TB banyak terjadi pada lelaki, usia produktif, dan dikalangan 
China. Jenis TB yang paling umum ialah TB paru dengan kebanyakan pesakit 
mengalami batuk, kahak smear positif, dan x-ray dada tidak normal. Tuberculosis 
kasus baru ialah yang banyak terjadi dan separuh dari pesakit memiliki penyakit lain. 
Hampir 1/3 (26.0%) pesakit TB ialah pesakit DM dan 8.1% pesakit HIV/AIDS. 
Sepenuhnya ada 103 (15.8%) pesakit mengalami kesan advers drug dan 17 (2.6%) 
pesakit muncul bakteri rintang ubat anti-TB. Kesan advers drug yang banyak terjadi 
ialah reaksi kulit, diikuti reaksi gastrointestin, reaksi hepatic, reaksi neurologi, dan 
reaksi lain. Kebanyakan pola bakteria rintang ubat anti-TB adalah yang rintang satu 
ubat anti-TB. Ujian statistik chi-square dilakukan untuk menganalisa faktor yang 
berkaitan dengan kesan advers drug dan bakteria rintang ubat anti-TB. Hasil kajian 
menunjukkan bahawa kesan advers drug berkaitan dengan pesakit dengan sejarah 
penggunaan alcohol, penyalahgunaan dadah, pesakit DM, dan pesakit HIV/AIDS. 
Bakteria rintang ubat anti-TB berkaitan dengan pesakit yang pernah mendapatkan 
rawatan TB sebelumnya. Rawatan untuk kesan advers drug yang terjadi sebagian 
besar adalah dengan memberi tambahan ubat untuk mengatasi munculnya kesan 
advers drug dan rawatan pada pesakit dengan bakteria rintang ubat anti-TB 
bergantung kepada keputusan ujian sensitiviti pesakit. Keputusan klinikal pesakit 
menunjukkan bahawa kebanyakan pesakit telah sembuh daripada jangkitan TB dan 
faktor yang berkaitan dengan keputusan klinikal adalah adanya bakteri rintang ubat 
anti-TB. 
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EXPLORATIVE STUDY OF ADVERSE DRUG REACTIONS AND DRUG-
RESISTANT TUBERCULOSIS AMONG TUBERCULOSIS PATIENTS 
IN HOSPITAL PULAU PINANG, MALAYSIA 
 
ABSTRACT 
 Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis 
claimed for human life throughout history today become second leading infectious 
diseases caused death after HIV-AIDS. Treatment of tuberculosis required 
combination of anti-tuberculosis drug. Anti-tuberculosis adverse drug reactions 
(ADRs) become important as longer use of these drugs. In addition to anti-
tuberculosis ADRs, the presence of tuberculosis bacteria that resistant to anti 
tuberculosis drug may complicate on tuberculosis treatment. 
This study was a retrospective cross-sectional observation study. Research 
subjects of this study were patients who were treated as active tuberculosis in Chest 
Clinic, Hospital Pulau Pinang, Malaysia. The aim of the study was to investigate 
anti-tuberculosis ADRs, drug-resistant tuberculosis (DR-TB), and all associate 
factors related to ADRs and DR-TB, also patients’ treatment clinical outcomes. 
Adverse drug reactions were detected from patients’ complains, clinical symptom, 
laboratory test result, and any other related information and DR-TB detected from 
patients’ sensitivity test result. Patients’ socio-demographic, medical history, 
tuberculosis diagnosis and treatment, clinical sign and symptom of ADRs, laboratory 
test result, sputum smear test, radiology test result, and other relevant information 
were collected. Obtained data then exported to excel and analyzed by using 
Statistical Package for Social Sciences (SPSS® version 15).  
xviii 
 
The study result showed that out of 653 patients included, TB cases most 
likely happened in male, productive age, and among Chinese. Most common type of 
TB was pulmonary TB with most of the patients had cough, sputum smear positive, 
and abnormal chest x-ray result. The most common of TB case was new diagnosed 
and half of the patients included had co-morbidity. Almost one third (26.0%) of TB 
patients were DM patients and 8.1% were HIV/AIDS patients. Totally 103 (15.8%) 
patients had an experience on ADRs and 17 (2.6%) patients with DR-TB. Common 
type of ADRs occurred was skin reaction, followed by gastrointestinal reaction, 
hepatic reaction, neurological reaction, and other reaction. Most of DR-TB pattern 
was mono-resistant tuberculosis in 10 patients. Chi-square test was implemented in 
order to asses associated factor related to ADRs and DR-TB. Study result showed 
that ADRs more likely related to alcohol consumption, drug abuse, patients with 
DM, and patients with HIV/AIDS infection. Drug-resistant tuberculosis more likely 
related to patient who had previous tuberculosis treatment (relapse patients). Adverse 
drug reaction management was mostly by giving other drug to overcome ADRs upon 
occurred and management on DR-TB depend on sensitivity test result. Clinical 
outcomes showed that most of the patients were cured from tuberculosis infection 
and factor that may affect on patients’ clinical outcome was ADRs occurrence.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
Tuberculosis (TB), a well known infectious disease caused by 
Mycobacterium tuberculosis today has become the second leading cause of death 
among infectious diseases in the world (Dale, 2003; Allman, 2007). Tuberculosis 
bacteria commonly infects human lungs (pulmonary TB), but it may also involve any 
other organ. Active pulmonary TB incidence globally is estimated around 8 million 
new cases per year (Gulbay et al., 2006). Mycobacterium tuberculosis infects one 
third of global population (Tang et al., 2006) and TB continues to kill an estimated 
1.8 million people globally each year (Anderson et al., 2010). 
Active TB has been noted as a complex and unpredictable disease that caused 
severe disabilities even death. On the other hand, the TB bacteria can also hide 
within the human body for decades without causing any harm to the body (Allman, 
2007). Tuberculosis causative bacteria can easily spread through air droplets while 
infected patients cough or sneeze, variety of hosts and environment related-factors to 
TB spreading (Parekh, 2009). Complexity of TB makes this disease remain as a 
global health problem not only in developing countries but also in developed 
countries, but a greater proportion of the illness lies in developing countries (Allman, 
2007; Nissapatorn et al., 2007). Tuberculosis remains a disease associated with 
crowded population, decreased immunity, and poverty (Tang et al., 2006).  
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1.2 Tuberculosis History and Epidemiology 
1.2.1 Tuberculosis History  
Tuberculosis already claimed human life for centuries throughout human 
history than any other diseases (Daniel, 2006; Allman, 2007; Kaufmann and Helden, 
2008). Earliest evidence of the occurrence of TB was an archeological excavation 
dated back to the Neolithic period (Kaufmann and Helden, 2008). Scientists 
discovered other evidences of TB in the bones of Egyptian mummies and prehistoric 
cave people. Tuberculosis seemed to have affected society independently in all part 
of the world (Allman, 2007). It reached epidemic proportion in Europe and North 
America during the 18th century then began to decline in the 19th century (Daniel, 
2006). In Malaysia, TB became the leading cause of death in early 1940s and 1950s 
(MOH, 2002). 
Pathogenesis of TB began to be understandable in the beginning of 19th 
century by the work of Laennec (Shampo and Rosenow, 2009). Transmission ability 
of Mycobacterium tuberculosis was demonstrated by a French physician, Jean 
Antoine Villemin in 1867 and identification of Mycobacterium tuberculosis as a 
causative agent or as the etiologic agent of TB was discovered by Robert Koch in 
1988, and was awarded a Nobel Prize in Physiology and Medicine for this (Daniel, 
2006; Shampo and Rosenow, 2009). 
Tuberculosis diagnosis uses tuberculin test which was developed by Clemens 
von Pirquet in 1907 and 3 years after that it was used to demonstrate latent TB 
infection in asymptomatic children (Shampo and Rosenow, 2009). Effective anti-TB 
agents have been available since 1940s (Volmink and Garner, 2009). Streptomycin 
and para-aminosalicylic acids were invented in the 1940‟s, in 1950‟s Isoniazid and 
Pyrazinamide, and in 1960‟s Ethambutol and Rifampicin (Parekh, 2009).  
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1.2.2 Tuberculosis Epidemiology  
Tuberculosis globally was monitored every year by the World Health 
Organization (WHO) and published TB reports since 1997 to outline the course of 
TB and to evaluate TB control worldwide (WHO, 2006). Tuberculosis cases which 
occurred from 2005 to 2010 can be seen in figure 1.1.  
Tuberculosis cases on a global scale were estimated to be around 8.8 million 
in 2005 with a total of 1.6 million people dying due to TB (WHO, 2007). In 2006, 
TB cases increased to 9.2 million new cases on a global scale with a total 1.7 of 
million deaths due to TB (WHO, 2008), while in 2007 TB new cases were estimated 
at 9.3 million with 1.8 million deaths from TB (WHO, 2009). In 2008 TB new cases 
were estimated to be 9.4 million of TB global scale, which increased from 9.3 
million TB case occurred in 2007 (WHO, 2009). Tuberculosis incidence cases in 
2009 were estimated to be 9.4 million of TB globally, same number of incidence 
cases in 2008 (WHO, 2010a). Globally, in 2010 new TB cases were estimated at 8.8 
million with 1.1 million deaths due to TB (WHO, 2011).  
Top five countries with TB incidence in 2008 were India (1.6–2.4 million), 
China (1.0–1.6 million), South Africa (0.38–0.57 million), Nigeria (0.37–0.55 
million) and Indonesia (0.34–0.52 million). An estimated 35% TB cases globally 
occurred in India and China alone (WHO, 2009).  
Tuberculosis cases globally in 2008 and 2009 was estimated to be about 9.4 
million most of the estimated number of TB cases occurred in Asia (55%) and Africa 
(30%), small proportions of TB cases occurred in the Eastern Mediterranean Region 
(7%), the European Region (5% in 2008, 4% in 2009) and the Region of the 
Americas (3%) (WHO, 2009; 2010a). 
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Figure 1.1 World Health Organizations, Tuberculosis Case Report 2005-2010  
 
 
Tuberculosis became the leading cause of death in Malaysia in early 1940s 
and 1950s.  Malaysia is a multi-ethnic country that consists of three major ethnic 
groups Malay, Chinese, and Indian (MOH, 2010). In 1999, Malaysia was ranked 46th 
in total number of TB cases globally with 14908 new cases of TB reported. Most of 
the TB cases were in the 15-50 age groups in Malaysia. Incidence rate of TB cases in 
Malaysia is 47 per 100,000 population per year with prevalence of 136 cases and 
mortality rate is estimated 17 cases per year (Marzuki et al., 2008), reported a total 
number of deaths due to TB was 853. This makes TB the single most important killer 
among other infectious disease in Malaysia (MOH, 2002). 
 
1.3 Tuberculosis Etiology and Pathology 
Tuberculosis caused by Mycobacterium tuberculosis, is an obligate aerobe 
bacillus with a size of about 0.2 x 5.0 µm. It most successfully grows in human 
tissues that have highest oxygen tension (PO2), such as the lung apexes; a slowly 
growing organism with generation time estimated to be 12 to 18 hours; has a high 
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cell-wall lipid content so the organism is impermeable to the usual bacteriologic 
stains and even this organism require special enriched media to grow in the 
laboratory, this organism is extremely resistant to physical stress (Dale, 2003). 
Tuberculosis pathogenesis is unique due to many related variables but mostly 
long latency period from someone infected to the clinical illness manifestation. A 
single TB bacillus theoretically can cause infection but it needs to pass the upper 
airway defense mechanism to reach alveoli of the pulmonary (Dale, 2003).  
Transmission of Mycobacterium tuberculosis is commonly spread from 
infected persons to another person by cough or sneeze that is dispersed by droplet 
nuclei in which each droplet may contain one to three bacilli (Peloquin, 2005). 
Development of TB infection may occur after inhalation of the infected droplets that 
has been sneezed out by infected by Mycobacterium tuberculosis (Actor et al., 2008).  
Primary infection is initiated when inhaled infectious droplets may escape 
from host‟s upper airway defenses and reach the alveoli (Peloquin, 2005), then the 
lungs exposed to TB bacteria (Actor et al., 2008). After inhalation, the TB bacteria 
grows intracellular in the host‟s alveolar macrophages, then followed by the 
recruitment of new macrophages and lymphocytes, and the formation of a 
tuberculous granuloma (Ridzan and Kizza, 2002). Disease progression on clinical 
manifestation depends on the number of organisms inhaled, virulence factors of the 
organism and host cell-mediated immune system (DiPiro et al., 2008).  
Growth periodicity of the bacilli is logarithmic in which single bacilli will 
duplicate every 24 hours. The bacilli can be spread from the initial lesion to the other 
parts of the body through lymphatic and or circulating system. The centre of the cell 
mass or granuloma become caseous and necrotic as the cellular infiltration continue  
(Nicholas et al., 2010).  
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The period of infectiousness on a patient may be prolonged due to late 
diagnosis, poor adherence to medications or inappropriate TB treatment that is 
caused by drug-resistant organisms (Ridzan and Kizza, 2002). 
 
1.4 Tuberculosis Risk Factors 
There are several factors that are responsible for developing TB infection 
including poverty, lack of modern treatment methods and AIDS epidemic (Allman, 
2007). Tuberculosis is mainly a disease of adults and it affects men more than 
women (Kaufmann and Helden, 2008), with high risk for TB in males within the age 
group 25 and 44 (Dale, 2003).  In the United State, in 2002, 35% among TB cases 
was within the age group 25 to 44 years, followed between 45 to 64 years (28%), and 
65 years of age above (21%) (Peloquin, 2005).  
Tuberculosis cases in relation to ethnicity and age, TB is more common in 
older whites and Asians compared to younger people from these groups. Older 
blacks and Hispanics also have more TB than younger folks, but the differences by 
age are not as pronounced. Until the age of 15, TB rates are similar for males and 
females, but after that, the male predominance increases with each decade of life 
(Peloquin, 2005). 
Tuberculosis disproportionately affects ethnic minorities in United States, 
non-Hispanic blacks accounted for 30% of all TB cases, followed by Hispanics at 
27%. Asians and Pacific Islanders accounted for 22%, whereas non-Hispanic whites 
accounted for only 20% of the new TB cases in 2002 (Peloquin, 2005). 
People that have close contact history of pulmonary TB patients are most 
likely to be infected, including family members, co-workers, or co-residents in places 
such as prisons, shelters, or nursing homes. The longer the contact with TB patients 
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the greater risk to be infected, with infection rates as high as 30%. Although many 
circumstances exist to be infected with TB, most TB patients have limited access to 
health care, living in crowded condition or homeless (DiPiro et al., 2008). 
Other groups of populations with high incidence of TB such as immigrants, 
alcoholic, drug dependant person, homelessness, people who travel to TB endemic 
countries, and hospital employees, including physicians are also at increased risk of 
infections with TB (Dale, 2003). 
Newly acquired TB infections cases occur every second in the world and in 
addition, one third of the world population is currently infected with Mycobacterium 
tuberculosis. Due to lack of healthy nutrition, crowded living conditions, and lack of 
access to health care, the highest incidence rate of TB cases is among developing 
countries (Tang et al., 2006). 
 
1.5 Tuberculosis Transmission 
Tuberculosis is a disease that can easily spread through air (Frieden et al., 
2003). Tuberculosis bacteria can spread by airborne droplets from patients that have 
been infected by TB to other humans. Passive case patients are identified mostly in 
high-burden countries when they visit health care facilities. Contact with patients 
with TB is a high-risk group for developing the disease, so that actively screening 
contacts with patients that confirmed TB may improve on case detection and control 
the disease (Fox et al., 2011).  
Air travel also gives opportunities for TB to spread rapidly between countries 
and continents. There may be potential risk of transmission during flights, notably 
airborne and droplet borne respiratory infection. Infected passengers may act as 
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disease vectors, bringing the infectious agents to the destination (Martinez et al., 
2007).  
There are some factors that determine the possibility of Mycobacterium 
tuberculosis transmission including number of organisms being expelled into the air, 
organisms concentration in the air, length of time an exposed person breathes the 
contaminated air, and presumably the immune status of the exposed individual. 
People with HIV-infection or with low immunity status more likely to become 
infected with Mycobacterium tuberculosis after exposure than persons with normal 
immunity and more likely to develop disease if they are infected (Dunlap et al., 
2000).  
 
1.6 Tuberculosis Clinical Manifestations  
1.6.1 Pulmonary Tuberculosis 
Definition of pulmonary TB is an active infection of the lung, means that the 
bacteria can located in the lung. Pulmonary infections are critically important 
because they are highly contagious and life threatening to patients that get affected 
(Davies et al., 2008). Suggested symptoms of pulmonary TB are cough (usually 
more than three weeks), cough with sputum, loss of appetite, loss of weight, fever, 
dyspnea, night sweats, chest pain and hoarseness of voice, all of which are not 
common. Patients with all these symptoms should be screened for TB (MOH, 2002). 
 
1.6.2 Extra-pulmonary Tuberculosis 
Extra-pulmonary TB is defined as tuberculosis infection in other organs 
besides the lung (Davis et al., 2008). Extra-pulmonary TB symptoms are often non-
specific, including lassitude, anorexia, fever, and weight loss. The specific features 
are related to the organ involved (MOH, 2002). 
9 
 
1.7 Tuberculosis Investigation  
The first technique in TB diagnosis was in 1882, Dr. Robert Koch, and Dr. 
Paul Erlich developed the acid-fast strain to identify Mycobacterium tuberculosis 
(Dye et al., 1999). Earlier diagnosis of TB is important to control the infection, to 
introduce timely manner of the treatment, and to determine bacteria resistance 
profile. Over the past two decades, dedicated efforts have resulted in enhancing TB 
diagnosis techniques (Tang et al., 2006). 
The main tool for diagnosis of adult pulmonary TB is the sputum smear 
examination by direct microscopy for acid-fast bacilli (AFB). Once someone 
experiences most of the common symptoms of TB (persistent cough for 3 weeks or 
more) they need to follow some screening tests by submitting 3 sputum samples. 
Diagnosis on adult TB is described in figure 1.2 (WHO, 1999).  
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Figure 1.2 Diagnosis of Adult Pulmonary Tuberculosis (WHO, 1999)   
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1.7.1 Microbiological Investigation 
Microbiological methods, smear, and culture for Mycobacterium tuberculosis 
remain as gold standards for definitive diagnosis but are insensitive when compared 
with microbiologic specimens for routine bacteria. Histology examination of tissue 
from various sites such as liver, lymph nodes, bone marrow, pleura or synovium that 
show the characteristic tissue reactions (caseous necrosis with granuloma formation) 
is useful for diagnosis of TB disease but not definitively indentified Mycobacterium 
tuberculosis as the causative agent, therefore culture should be obtained whenever 
possible. For suspected pulmonary TB, three consecutive morning sputum specimens 
are recommended for mycobacterial studies that include an initial smear and culture 
for Mycobacterium tuberculosis (Marion and High, 2009).  
Mycobacterial culture is considerably more sensitive than microscopy for the 
diagnosis of TB (Lam et al., 2010). Classic culture using egg-based media takes up 
to 8 weeks for final result. There are radiometric methods such as BACTEC, which 
can give us result within 2 weeks that can be use for early diagnosis and in smear 
negative patients (MOH, 2002).  
 
1.7.2 Chest X-Ray 
A plain chest X-ray is usually preliminary radiological investigation in 
suspected TB (Parekh, 2009). Radiographic findings, like other diagnostic 
modalities, vary with age. Cavitations are more common in young than older adults 
with pulmonary TB. Further, young patients have more upper lobe infiltration while 
older patients are more likely to have a milliary or nonspecific pattern on chest 
radiograph (Marion and High, 2009). 
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1.7.3 Tuberculin Skin Test (TST)/ Mantoux 
 Tuberculin is a glycerin extract from the tubercle bacillus. Tuberculin skin 
test is important for diagnosis and prevention of TB that is more sensitive than Chest 
X-ray in identifying Mycobacterium tuberculosis infection. The tuberculin skin test 
should be evaluated within 48 to 72 hours after the patient is injected (Dale, 2003). 
Diameter of induration rather than erythema determines the interpretation. The 
American Thoracic Society and the Centre for Disease Control and Prevention 
(CDC) now proposes that different criteria must be applied to different population 
groups. Criteria for positive tuberculin skin testing shown in table 1.1. 
 
Table 1.1 Criteria for Positive Tuberculin Skin Test in Different Risk Condition 
(DiPiro et al., 2008) 
≥ 5 mm induration ≥ 10 mm induration ≥ 15 mm induration 
HIV positive patients 
 
 
 
A recent contact of a person 
with TB disease 
 
 
 
Persons with fibrotic changes 
on chest radiograph consistent 
with prior TB 
 
 
Patients with organ transplants 
 
Persons who are immune-
suppressed for other reasons 
(e.g., taking the equivalent of 
>15 mg/day of prednisone for 
1 month or longer, taking 
TNF- a antagonists 
Recent immigrants (within 5 
years) from high prevalence 
countries 
 
Injection drug users 
 
 
 
 
Residents and employees of 
high-risk congregate settings 
(includes long term care 
facilities) 
 
Mycobacteriology laboratory 
personnel 
 
Persons with clinical 
conditions* that place them at 
high risk 
 
 
 
 
Children <4 years of age, 
infants, children, and 
adolescents exposed 
to adults in high-risk categories 
 
Any person, including 
persons with not known risk 
factors for TB. 
 
However, targeted skin 
testing programs should only 
be conducted among high-
risk groups 
 
Adapted from Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk 
populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995; 44 (RR: 11): 
19-34 
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The disadvantage of tuberculin skin test it is time consuming. It may have 
more of a role in low TB-prevalent areas where HIV infection is also uncommon 
(Dale, 2003). Although tuberculin proved ineffective as a remedy for TB  it was 
immediate discovery that repeated injections caused more rapid and severe skin 
reactions (Parekh, 2009). 
 
1.7.4 Polymerase Chain Reaction (PCR) 
Nucleic Acid Amplification Tests (NAA Test) are developed for rapid 
diagnosis of tuberculosis disease. In this method, mycobacterial DNA and RNA are 
directly detected in clinical specimens (Tang et al., 2006). Nucleic Acid 
Amplification Test by polymerase chain reaction can detect small numbers of 
organism. However PCR can give positive result in patients who are already on anti-
TB treatment but still excreting small number of non-viable bacilli, thus this test not 
for patients‟ follow up of treatment (MOH, 2002). 
 
1.8 Anti-Tuberculosis Drugs Regimen 
The chemotherapy for pulmonary and extra-pulmonary TB is similar and 
should proceed according to 1). Cultures and drug sensitivity test results, 2). 
Combination of anti-TB drugs must be used. The most important reason for using 
two or more chemotherapy agents simultaneously is to prevent the emergence of 
drug-resistant TB organism, 3). Daily single dose of anti-TB drugs is preferred. 
Single-dose therapy is as effective as divided-dose therapy, because due to slow 
generation time of the tubercle bacillus achieves greater patients‟ acceptance and 
compliance, 4). Prolonged chemotherapy is necessary. Previous regimens used 
multiple drugs for period of 18 to 24 months, but with combinations of newer agents, 
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shorter regimens of 6 months have been found to be equally effective, and 5) Patients 
are closely followed up to ensure patients compliance, also to monitor drug efficacy 
and toxicity (Dale, 2003). 
Treatment for TB of active disease, initial four-drug therapy is recommended, 
but, if the organism is isolated and susceptibility testing results are available, can be 
tapered to two-drug specific combination therapies (Marion and High, 2009). 
Modern anti-TB drug was started by the discovery of streptomycin in 1944 
by Schatz, Bugie, and Waksman, then para-amino-salicylate was discovered by 
Lehmann two years later (Zhang and Amzel, 2002). Main aims of anti-tuberculosis 
drug therapy are to eradicate all active metabolites bacteria in the pulmonary and 
eliminate less active replicates and near dormant bacteria that may cause disease 
relapse (Rivers and Mancera, 2008). Anti-TB drugs can be divided into first-line 
drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin) and 
second line drugs (para-amino-salicylic acid, cyloserine, ethionamide, quinolones, 
etc) (Peloquin, 2005). First-line anti-TB drug regimen primarily consists of isoniazid 
and rifampicin, and has already been used for many years for TB treatment and 
evidently effective in active, drug-susceptible TB, when patients have completed 
their course of treatment (Rivers and Mancera, 2008). 
Isoniazid, one of the most important anti-TB drugs, that is highly specific for 
mycobacteria (Peloquin, 2005), is a pro-drug that needs to be activated by bacterial 
catalase-perokxidase to generate reactive oxygen species and reactive organic 
radicals, that then attack multiple targets in the tubercle bacillus (Zhang and Amzel, 
2002).   
Rifampicin interrupts on RNA synthesis by binding to the bacterial DNA-
dependent RNA polymerase β-subunit (Zhang and Amzel, 2002) while streptomycin 
15 
 
inhibits initiation of mRNA translation, and facilitates genetic code misreading and 
ribosome inefficient proofreading (Zhang and Amzel, 2002).  
Ethambutol affects the biosynthesis of major polysaccharide of mycobacterial 
cell wall (arabinoglactan) (Zhang and Amzel, 2002).   
Pyrazinamide mechanism of action is by disruption of membrane function 
and energy metabolism, pyrazinamide is a nicotinamide analog also a prodrug that 
needs to be activated as pyrazinoic acid by the nicotinamidase enzyme (Zhang and 
Amzel, 2002). Mechanism action of anti-TB drugs can be seen in table 1.2.  
 
Table 1.2 Anti-tuberculosis Drugs and their Targets (Zhang and Amzel, 2002)  
Drugs Mechanism of action Targets 
Isoniazid  Inhibition of cell wall mycolic acid 
synthesis, and 
other potential multiple effects on 
DNA, lipids, 
carbohydrates, and NAD metabolism 
Multiple target including 
acyl carrier protein reductase 
(InhA), β-ketoacyl synthase 
(KasA) 
Rifampicin Inhibition of RNA synthesis RNA polymerase unit 
Pyrazinamide Distruption of membrane function and 
energy 
Membrane function and 
energy metabolism 
Ethambutol  Inhibition of cell wall arabinogalactan 
synthesis 
Arabinosyl transferase 
Streptomycin  Inhibition of protein synthesis Ribosomal S12 protein and 
16SrRNA 
Amikacin/Kanamycin 
/Capreomycin 
Inhibition of protein synthesis 16SrRNA 
Fluoroquinolones Inhibition of DNA gyrase DNA gyrase 
Ethionamide Inhibition of mycolic acid synthesis Acyl carrier protein 
reductase (InhA) 
Cycloserine Inhibition of peptidoglycan synthesis D-alanine racemase/synthase 
Para-amino-salicylic acid Inhibition of folic acid synthesis  Unknown 
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1.8.1 World Health Organization Tuberculosis Treatment’s Guidelines 
According to WHO, the aims of TB treatment are to cure patients and to 
restore patients‟ quality of life and productivity; to prevent patients‟ death due to 
active TB or its late effects; to prevent TB relapse; to reduce TB transmission to 
other person and to prevent drug resistant TB development and transmission (WHO, 
2010b). Most TB treatments need more than one drug combination to eradicate TB 
bacteria. First line anti-TB drugs recommended for TB treatment by WHO are 
combination between isoniazid, rifampicin, pyrazinamide, ethambutol and 
streptomycin (WHO, 2010b). Anti-TB drugs standard regimens recommended by 
WHO can be seen on the table 1.3.  
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Table 1.3 Standard Treatment Regimens for TB Treatment (WHO, 2010b) 
Tuberculosis status Intensive Phase Treatment Continuation Phase 
Treatment 
Regimens Freq/Duration Regimens Freq/Duration 
New tuberculosis patient (presumed, or known, to have drug susceptible TB 
Standard regimen new TB patients HRZE Daily/2 months HR Daily/4 months 
Acceptable alternative for any new 
TB patient receiving directly observed 
therapy 
HZRE Daily/2 months HR Three times per 
week/4 months 
Acceptable alternative provided that 
patient is receiving directly observed 
therapy and is not living with HIV or 
living in an HIV prevalent setting 
HRZE Three times per 
week/2 months 
HR Three times per 
week/4 months 
In setting where the level of isoniazid 
resistance among new TB cases is 
high and isoniazid susceptibility 
testing is not done (result not 
available) before the continuation 
phase begins 
HRZE Daily/2 months HRE Daily/4 months 
Previously treated patients (relapse or defaulted) 
Standard regimens for previously treated patients depend on specimen for culture and drug susceptibility 
testing (DTS) result. DTS should be taken for at least isoniazid and rifampicin. 
In setting with conventional DTS 
method yield result within weeks or 
month, need to establish empirical 
regimens 
HRZES Daily/2 months HRZE 
 
HRE 
Daily/1 months 
Daily/5 months 
In country with rapid DTS method  Depend on DTS result if there are any drug resistant 
tuberculosis occurred use the drug resistant regimens 
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Recommended standard doses of each first-line anti-TB drug for adult by 
WHO can be seen in table 1.4. 
 
Table 1.4 Recommended Doses of First-Line Anti-Tuberculosis Drugs for Adult 
Drug Recommended dose 
Daily 3 Times per week 
Dose and range 
(mg/kg body weight) 
Maximum 
(mg) 
Dose and range 
(mg/kg body weight) 
Maximum 
(mg) 
Isoniazid 5 (4-6) 300 10 (8-12) 900 
Rifampicin 10 (8-12) 600 10 (8-12) 600 
Pyrazinamide 25 (20-30) - 35 (30-40) - 
Ethambutol 15 (15-20) - 30 (25-35) - 
Streptomycina 15 (12-18)  15 (12-18) 1000 
aPatients aged over 60 years may not be able to tolerate more than 500–750 mg daily, so some guidelines recommend 
reduction of the dose to 10 mg/kg per day in patients in this age group (2). Patients weighing less than 50 kg may not tolerate 
doses above 500–750 mg daily (WHO Model Formulary 2008, www.who.int/selection_medicines/list/en/ 
  
Recommended second-line anti-TB drugs are cycloserine, ethionamide, 
streptomycin, amikacin-kanamycin, capreomycin, p-aminosalicylic acid (PAS) and 
levofloxacin, this second line drugs to substitute first-line anti-TB drugs in some 
certain case (DiPiro et al., 2008).   
 
1.8.2 Ministry Of Health Malaysia Treatment’s Guidelines 
Modern therapy should cure almost all new diagnosed patients if an effective 
regimen is prescribed for an adequate period of time and if the patient ingests the 
prescribed medication regulary. A six months course of therapy has proven highly 
effective and reliable. Purposes of the treatment are to reduce morbidity, to prevent 
mortality, to prevent relapse of TB, to decrease transmission, and to prevent the 
emergence of multidrug-resistant TB (MDR-TB) (MOH, 2002). 
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Table 1.5 Anti-Tuberculosis Drugs and Recommended Dosage (MOH, 2010)  
First line drug Daily dosage Biweekly dosage 
mg/kg max (mg) mg/kg max (mg) 
Isoniazid (H) 5 – 8 300 15 - 20 1200 
Rifampicin (R) 10 – 15 600 15 – 20 600 
Pyrazinamide (Z) 20 – 40 1500 50 3000 
Ethambutol (E) 15 – 25 1200 50 2000 
Streptomycin (S) 15 – 20 1000 15 – 20 1000 
Note : For patient more than 65 years of age, the dose of streptomycin should not exceed 750 mg 
 
 
Dosage regimen from MOH is almost the same as the dosage form 
recommended by World Health Organization. Figure 1.3 showed TB treatment 
categories in Malaysia accordingly to Ministry of Health Malaysia 2002. There are 
no newest guidelines regarding to TB treatments regimen. MOH categorizes TB into 
three categories, category I: new TB case, category II: for relapse patients and failure 
after interruption patients, and category III: patients with chronic case. 
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Figure 1.3 Treatment Categories and Regimen (MOH, 2010) 
 
1.9. Adverse Drug Reactions (ADRs) 
1.9.1. Definition of Adverse Drug Reactions 
Adverse drug reaction is unwanted or unintended effect of medicines which 
occur during proper use of drugs. Definition of ADRs according to WHO is any 
noxious and unintended response of drugs that occurs at doses used for prophylaxis, 
diagnosis or therapy. Drug side effect definition, is any unintended effect of a 
pharmaceutical product that occur at normal dose usage which is related to the 
Treatment Categories 
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2EHRZ or 
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i). Send 
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and sensitivity 
ii). Do not initiate 
standart therapy 
iii). Refer to chest 
physician or 
physician in charge 
of chest clinic 
iv). Subsequent drug 
regimen based on 
sensitivity result and 
clinical response. 
Continuation phase: 
4H2R2 or 
4S2H2R2 or 
4HR or 
4H3R3 or 
4S3H3R3 
(duration may be 
extended for severe 
forms of 
extrapulmonary 
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immuno-compromised 
patients) 
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pharmacological properties of the drug (Badyal and Bhatia, 2006). The simplest 
classification of ADRs is into type A and B reactions. The differences of those 2 
types of ADRs can be seen in table 1.6. 
 
Table 1.6 Differences of ADRs Type (Badyal and Bhatia, 2006)  
 Type A Type B 
Drug response Augmented  Bizarre  
Pharmacologically predictable Yes  No  
Possible to reproduce in animals Usually possible Difficult 
Dose-dependent Yes  No  
Dependence on host Often independent Usually dependent 
Incidences  High  Low  
Morbidity  High  Low 
Mortality  Low  High  
Treatment  Dose adjustment Stop  
 
Adverse drug reactions are common and often preventable causes of hospital 
admission, which has become an important challenge in today‟s modern medicine in 
terms of early recognition, proper management, and avoidability (Farcas et al., 
2010). Although prescribers aim to use medicines that help patients and do no harm, 
no drug is administered without risk. Minimizing the occurrence of ADRs is the 
main challenge to do this effectively requires an understanding of their frequency, 
severity, predictability and reversibility. It is also helpful to have an appreciation of 
the patient groups that are predisposed to drug toxicity (Lee, 2001).  
 
The diagnosis of an adverse reaction is the difficult part, if a patient taking 
medicines in differential diagnosis should include the possibility of ADRs (Edwards 
and Aronson, 2000). The  most  important  problem in  assessing  ADRs is whether 
there is a  causal  relationship  between  the  drug  and  the untoward  clinical  event 
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(Naranjo et al., 1981). The Naranjo Algorithm is a questionnaire designed by 
Naranjo et al in order to determine the possibility of whether an ADRs is actually 
due to the drugs rather than the result of other factors. The probability is defined 
through a score termed definite, probable, possible, and doubtful (Doherty, 2009).  
Study on ADRs showed that antibiotics were responsible for 44.9% out of 
250 episodes of ADRs observed in two pulmonology division of Catanzaro, Italy 
(Gallelli et al., 2002). 
 
1.9.2 First-line Anti-tuberculosis Drugs Profile  
First-line anti-TB that is commonly used in TB treatment is a combination of 
two or more anti-TB drugs such as  isoniazid, rifampicin, pyrazinamid, ethambutol, 
and streptomycin. The necessity of using of multidrug regimens has been associated 
with increased incidence of ADRs of anti-TB drugs. This ADRs may be mild as well 
as fatal (Gulbay et al., 2006).  
Anti-TB agent that is commonly used such as, isoniazid, rifampicin and 
pirazinamide are highly effective but also can cause hepatotoxicity (Singla et al., 
2010). Treatment of people with TB requires treatment for at least six months, and 
sometimes patients may find difficulty in completing their treatments. This poses a 
major constraint to eradicating the disease (Volmink and Garner, 2009). Drug‟s 
profile of first-line anti-TB drugs is listed on table 1.7.  
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Table 1.7 First-line Anti-Tuberculosis Drugs Profile (Lacy et al., 2008).  
Anti-tuberculosis 
Drugs 
Drugs Profile (Precaution, ADRs and Monitoring) 
Isoniazid Warnings/precaution: use with caution in patients with severe renal impairment and liver 
disease 
Adverse Drug Reactions:  
a. Cardiovascular: hypertension, palpitation, tachycardia, vasculitis 
b. CNS: depression, dizziness, encephalopathy, fever, lethargy, memory impairment, 
seizure, slurred speech, 
c. Dermatologic: flushing, rash, Endocrine and metabolic: hyperglycemia, metabolic 
acidosis, pellagra, pyridoxine deficiency,  
d. GI: anorexia, nausea, vomiting, stomach pain 
e. Hematologic: agranulocytosis, anemia (sideroblastic, hemolytic or aplastic), 
eosinophilia, thrombocytopenia 
f. Hepatic: hyperbillirubinemia, billirubinuria, jaundice, hepatitis, hepatic dysfunction 
g. Neuromuscular and skeletal: athralgia  
h. Ocular: blurred vision, loss of vision, optic neuritis and atrophy 
i. Miscellaneous: Lupus-like syndrome, lymphadenopathy, rheumatic syndrome. 
Monitoring parameters: baseline and periodic LFT; sputum cultures monthly  
Rifampicin Warnings/precaution: in liver impairment (caution n modify dosage) 
Adverse Drug Reactions: 
a. Cardiovascular: edema, flushing 
b. CNS: ataxia, behavioral changes, concentration impairment, dizziness, drowsiness, 
fatigue, fever, headache, numbness, psychosis. 
c. Dermatologic: pemphigoid reaction, pruritis, urticaria  
d. Endocrine and metabolic: adrenal insufficiency, menstrual disorder 
e. Hematologic: agranulocytosis (rare), DIC, eosinophilia, hemoglobin decreased, 
hemolysis, hemolytic anemia, leukopenia, thrombocytopenia 
f. Hepatic: hepatitis (rare), jaundice 
g. Neuromuscular and skeletal: myalgia, osteomalacia, weakness 
h. Ocular: exudative conjungtivitis, visual changes 
i. Miscellaneous: flu like syndrome 
j. GI (1-2%): anorexia, cramps, diarrhea, epigastric distress, flatulence, heart burn, 
nausea, pancreatitis vomiting 
Monitoring parameters: periodic (baseline and every 2-4 weeks during therapy) LFT, 
CBC, hepatic n mental status, sputum culture, chest X-ray 
Pyrazinamide Warnings/precaution: use with caution in patients with history of alcoholism, renal failure, 
chronic gout, DM or porphyria  
Adverse Drug Reactions: 
1% to 10% 
a. CNS : malaise 
b. GI : anorexia, nausea, vomiting 
c. Neuromuscular and skeletal : athralgia, myalgia  
<1% (limited to important to life-threatening) : acne, angiodema (rare), anticoagulant 
effect, dysuria, fever, gout, hepatotoxicity, interstitial nephritis, itching, photosensitivity, 
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porphyria, rash, sideroblastic anemia, thrombositopenia, urticaria  
Monitoring parameters : periodic LFT, serum uric acid, sputum culture, chest X-ray 2-3 
months into treatment and at completion.  
Ethambutol Adverse Drug Reactions: 
a. Cardiovascular: myocarditis, pericarditis  
b. Central Nervous System: headache, confusion, disorentation, malaise, mental 
confusion, fever, dizziness, hallucination 
c. Dermatologic: rash, pruritis, dermatitis, exfoliative dermatitis 
d. Endocrine and metabolic: acute gout or hyperuricemia  
e. Gastrointestinal: abdominal pain, anorexia, nausea, vomitting  
f. Hematologic: leukopenia, thrombocytopenia 
g. Hepatotoxicity, hepatitis 
h. Neuromuscular and skeletal: Arthralgia  
i. Ocular: optic neuritis ; symptom may include decrease acuity, scotoma, color 
blindness, or visual defects (usually reversible with discontinuation, irreversible 
blindness has been described) 
j. Renal: nephritis 
k. Respiratory: infiltrates, pneumonitis  
l. Anaphylaxis  
Monitoring parameters, baseline and periodic (monthly) visual testing (each eye 
individually as well as both eyes tested together); baseline and periodic renal, hepatic and 
hematopoietic tests. 
Streptomycin Warnings/precaution: May cause neurotoxicity, nephrotoxicity, and/or neuromuscular 
blockade and respiratory paralysis 
Adverse Drug Reactions: 
a. Cardiovascular: hypotension 
b. CNS: neurotoxicity, drowsiness, headache, drug fever, paresthesia  
c. Dermatologic: skin rash 
d. GI: nausea, vomiting 
e. Hematologic: eosinophilia, anemia 
f. Neuromuscular and skeletal: athralgia, weakness, tremor 
g. Otic: ototoxicity (auditory), ototoxicity (vestibular) 
h. Renal: nephrotoxicity  
i. Respiratory: difficulty in breathing  
Monitoring parameters: hearing (audiogram), BUN, creatinine; serum concentration of the 
drug should be monitored  
 
 
1.10. Drug-Resistant Tuberculosis (DR-TB) 
There are many reasons that TB still became world health problem including 
poverty, social deprivation and also lack of health services in certain countries 
(Breathnach et al, 1998). Increasing incidence of Mycobacterium tuberculosis strain 
